Thursday, June 15, 2017 12:21:22 PM
With a growing consensus in the global health community that Hepatitis C (HCV) could be eliminated, a new report from the O'Neill Institute for National and Global Health Law at Georgetown University highlights a key missing element needed to achieving complete eliminationâ€"adequate surveillance and monitoringâ€"and explains how modest investments would improve lives and save money. The report was published June 13 ahead of the National Viral Hepatitis Roundtable congressional briefing June 14.
The Centers for Disease Control and Prevention (CDC) estimates that at least 3.5 million Americans currently have HCV infection, and rates of new infections have increased nearly 2.9-fold between 2010 and 2015. The latest data from 2015 indicate that an estimated 33,900 new infections occurred that year alone.
The report, "Monitoring the Hepatitis C Epidemic in the United States: What Tools are Needed to Achieve Elimination?" explains that effective medicines are available to treat and often cure hepatitis C, but information is lacking to know where to "deploy critical public health and health care resources to prevent new infections, screen and diagnose cases, and treat all of those who are infected with the virus," write the authors.
Written by Institute Associate Sonia L. Canzater, JD, MPH and Jeffrey S. Crowley, MPH, program director of infectious disease initiatives and distinguished scholar at the O'Neill Institute, the report was developed following an expert consultation held in Washington, DC, in September 2016 with diverse stakeholders, including hepatitis C medical and non-medical providers, patient advocates, epidemiologists, and federal hepatitis C policy and program staff.
Crowley and Canzater identify five critical actions that should be priorities for monitoring HCV: 1) expand and standardize reporting to the CDC, 2) utilize electronic medical records to collect data on HCV cases and the cure cascade, 3) fund epidemiologic research using clinical data sets, 4) integrate improved monitoring of HCV with responses to the opioid epidemic, and 5) establish and monitor HCV elimination plans across major US health systems.
"Even with a constrained federal budget, more resources are needed for HCV surveillance and monitoring," Crowley said, adding, "Relatively modest investments, however, can have a big impact toward eliminating HCV."
Canzater said that, "Most of the newly infected HCV cases are among injection opioid drug users, but we often do not have even basic information to adequately monitor where and how the HCV epidemic is unfolding in the US and we are not using the clinical data that is already collected." Canzater and Crowley say eliminating HCV would lead to a plummet in liver cancer rates (HCV was responsible for half of the nearly 23,000 liver cancer deaths in 2010). Almost $300 million a year in health care costs could be saved by avoiding the liver transplant surgeries caused by HCV.
Canzater and Crowley conclude, "Unlike some pressing problems where the scope of need is so large it can be immobilizing, modest new investments can have a significant impact. Boosting the capacity to monitor the HCV epidemic can move the nation toward eliminating HCV as a public health threat in the United States."
The report is available for free on the O'Neill Institute website: http://www.law.georgetown.edu/oneillinstitute/research/HepatitisCEpidemic.cfm
Story Source:
Materials provided by O'Neill Institute for National & Global Health Law. Note: Content may be edited for style and length.
Recent AEMD News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 12:01:08 PM
- Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India • PR Newswire (US) • 09/19/2024 12:01:00 PM
- Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial • PR Newswire (US) • 09/16/2024 12:01:00 PM
- Aethlon Medical to Present at the Life Sciences Investor Forum September 19th • GlobeNewswire Inc. • 09/13/2024 12:35:00 PM
- Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys • PR Newswire (US) • 08/27/2024 12:01:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/15/2024 08:34:03 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/15/2024 08:32:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/15/2024 08:30:33 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 08/15/2024 08:15:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:10:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:15:21 PM
- Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update • PR Newswire (US) • 08/14/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:01:08 PM
- Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 08/12/2024 12:01:00 PM
- Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024 • PR Newswire (US) • 08/06/2024 01:12:00 PM
- Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update • PR Newswire (US) • 06/27/2024 08:15:00 PM
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024 • PR Newswire (US) • 06/21/2024 12:01:00 PM
- Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 06/18/2024 12:01:00 PM
- Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies • PR Newswire (US) • 06/03/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 05:24:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:05:28 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/16/2024 08:05:23 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM